1. Home
  2. PSTG vs BIIB Comparison

PSTG vs BIIB Comparison

Compare PSTG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Storage Inc.

PSTG

Pure Storage Inc.

HOLD

Current Price

$67.30

Market Cap

23.0B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$183.51

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTG
BIIB
Founded
2009
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.0B
27.3B
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
PSTG
BIIB
Price
$67.30
$183.51
Analyst Decision
Buy
Buy
Analyst Count
19
27
Target Price
$90.05
$202.92
AVG Volume (30 Days)
2.2M
1.2M
Earning Date
05-27-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
77.42
N/A
EPS
0.55
8.79
Revenue
$3,662,843,000.00
$9,890,600,000.00
Revenue This Year
$21.76
N/A
Revenue Next Year
$15.70
N/A
P/E Ratio
$123.45
$21.37
Revenue Growth
15.61
2.22
52 Week Low
$43.51
$115.28
52 Week High
$100.59
$202.41

Technical Indicators

Market Signals
Indicator
PSTG
BIIB
Relative Strength Index (RSI) 60.46 51.75
Support Level $64.57 $181.24
Resistance Level $76.63 $184.16
Average True Range (ATR) 2.80 4.52
MACD 0.86 1.26
Stochastic Oscillator 100.00 61.34

Price Performance

Historical Comparison
PSTG
BIIB

About PSTG Pure Storage Inc.

Pure Storage Inc is a U.S.-based company that provides an enterprise data storage platform that transforms business through a dramatic increase in performance and reduction in complexity and costs. It generates revenue from two sources: product revenue, which includes the sale of integrated storage hardware and embedded operating system software; and subscription services revenue, which includes Evergreen Storage subscriptions, a unified subscription that includes Pure as-a-Service, Cloud Block Store, and Portworx. Subscription services revenue also includes professional services offerings such as installation and implementation consulting services.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: